Cytoreductive radiotherapy combined with abiraterone in metastatic castration-resistance prostate cancer: a single center experience
نویسندگان
چکیده
Abstract Background To investigate the potential benefit of cytoreductive radiotherapy (cRT) in metastatic castration-resistant prostate cancer (mCRPC) patients receiving abiraterone. Methods From February 2014 to 2019, 149 mCRPC treated with abiraterone were identified. Patients cRT before failure (AbiRT group) matched by one-to-two propensity score without (non-AbiRT group). Results The median follow-up was 23.5 months. Thirty (20.1%) AbiRT group, whereas 119 (79.9%) non-AbiRT group. 2-year OS managed and 89.5% 73.5%, respectively ( P = 0.0003). On multivariate analysis, only (HR 0.17; 95% CI 0.05–0.58; 0.004) prognostic index 2.71; 1.37–5.35; significant factors. After matching, continued be associated improved (median not reached vs. 44.0 months, 0.009). Subgroup analysis revealed that aged ≤ 65 years 0.09; 0.01–0.65; 0.018), PSA 20 ng/mL 0.29; 0.09–0.99; 0.048), chemotherapy-naïve upon treatment 0.20; 0.06–0.66; 0.008) intermediate prognosis groups COU-AA-301 0.13; 0.03–0.57; 0.007) had AbiRT. Conclusions resistance may improve survival selected patients: age old, chemotherapy-naïve, a relatively low level at diagnosis prognosis.
منابع مشابه
Re: Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.
BACKGROUND Abiraterone acetate, a drug that blocks endogenous androgen synthesis, plus prednisone is indicated for metastatic castration-resistant prostate cancer. We evaluated the clinical benefit of abiraterone acetate plus prednisone with androgen-deprivation therapy in patients with newly diagnosed, metastatic, castration-sensitive prostate cancer. METHODS In this double-blind, placebo-co...
متن کاملAbiraterone acetate: in metastatic castration-resistant prostate cancer.
Oral abiraterone acetate, in combination with prednisone/prednisolone, is used to treat patients with metastatic castration-resistant prostate cancer (CRPC) who have previously received docetaxel-containing chemotherapy. Abiraterone acetate was developed to specifically inhibit cytochrome P450 (CYP)17A1, which is an essential enzyme in the biosynthesis of testosterone. In a pivotal phase III tr...
متن کاملAbiraterone acetate for metastatic castration-resistant prostate cancer post-docetaxel
Abiraterone acetate (AA) 1000-mg daily, a selective irreversible androgen biosynthesis inhibitor of cytochrome P450 c17 (CYP17) enzyme, is used in combination with prednisone 10-mg daily to treat docetaxel-treated patients with metastatic castration-resistant prostate cancer (mCRPC). Several studies have demonstrated the safety and efficacy of this compound in men with mCRPC. Interim results fr...
متن کاملComplete Radiologic Response in Metastatic Castration-Resistant Prostate Cancer Treated with Cabazitaxel
متن کامل
Single Orbital Metastasis in Castration-Resistant Prostate Cancer
Introduction: Orbital metastasis of prostate cancer (PC) is very rare and even more unique in castration-resistant PC (CRPC). In this scenario, choline positron emission tomography/computed tomography (choline PET/CT) is the gold-standard restaging method of choice available in our setting, and new anti-androgens treatments show improvement in overall survival. Case presentation: We report the...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Radiation Oncology
سال: 2021
ISSN: ['1748-717X']
DOI: https://doi.org/10.1186/s13014-020-01732-y